Federal contractor · public award history
AMGEN USA INC
Parent: AMGEN USA INC Y6NEW42XK544
- Awards we know about
- 7
- Typical size
- $811,924
- Middle of their public awards
- Dollars on those awards
- $714.77M
Most of their awards we can see fall roughly between $438,701 and $357.35M.
From official USAspending contract records — not a capability rating, past-performance score, or recommendation to team or bid.
Public award activity by year
Sum of award values in our USAspending index (not a full financial history).
- 2024$65,478
- 2025$714.70M
Awarding agencies
- Department of Veterans Affairs (5)
- Department of Health and Human Services (2)
Industries & product codes
Award history
- Department of Veterans Affairs—
65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD
- Department of Veterans Affairs—
NEW AWARD FOR TRASTUZUMAB WITH AMGEN. ORDERING PERIOD IS NOV 15, 2025 THROUGH NOV 14, 2026 WITH FOUR ONE-YEAR OPTIONS.
- Department of Health and Human Services$713.89M
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.
- Department of Health and Human Services$811,924
VENDOR MANAGED INVENTORY (VMI) SERVICES FOR USG PROCURED 165,906 DOSES OF NEULASTA PRODUCT TO MITIGATE INJURIES CAUSED BY EXPOSURE TO CHEMICAL, BIOLOGICAL THREAT AGENTS, PHYSICAL, RADIOLOGIC AND NUCLEAR EXPOSURES.
- Department of Veterans Affairs—
2 LINE ITEMS CALCITONIN GENE-RELATED PEPTIDES (CGRP) AWARDED FOR A BASE YEAR PERIOD OF 2/26/2025 TO 2/25/2026 PLUS FOUR ONE-YEAR OPTION PERIODS.
- Department of Veterans Affairs—
ERENUMAB-AOOE 70MG/ML AUTOINJECTOR 1ML ERENUMAB-AOOE 140MG/ML AUTOINJECTOR 1ML
- Department of Veterans Affairs$65,478
TAVNEOS (AVACOPAN)
Intelligence only — not legal advice, not a past-performance evaluation, and not a recommendation to team or bid. Verify on USAspending and SAM.gov.